Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL.
10.1016/j.gpb.2018.12.008
- Author:
Qiong ZHANG
1
;
Hui HU
1
;
Si-Yi CHEN
1
;
Chun-Jie LIU
1
;
Fei-Fei HU
1
;
Jianming YU
2
;
Yaohui WU
3
;
An-Yuan GUO
4
Author Information
1. Hubei Bioinformatics and Molecular Imaging Key Laboratory, Department of Bioinformatics and Systems Biology, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
2. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
3. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: wuyaohui@hust.edu.cn.
4. Hubei Bioinformatics and Molecular Imaging Key Laboratory, Department of Bioinformatics and Systems Biology, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China. Electronic address: guoay@hust.edu.cn.
- Publication Type:Clinical Trial
- Keywords:
B-ALL;
CAR-T;
Regulatory network;
Transcriptome profile;
lncRNA
- MeSH:
Adult;
Antigens, CD19;
metabolism;
Bone Marrow;
metabolism;
CD8-Positive T-Lymphocytes;
immunology;
Female;
Gene Expression Regulation, Leukemic;
Gene Regulatory Networks;
Humans;
Immunotherapy, Adoptive;
Male;
MicroRNAs;
genetics;
metabolism;
Middle Aged;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
genetics;
immunology;
therapy;
RNA, Long Noncoding;
genetics;
metabolism;
Receptors, Antigen, T-Cell;
Transcription Factors;
metabolism;
Transcriptome;
genetics
- From:
Genomics, Proteomics & Bioinformatics
2019;17(2):190-200
- CountryChina
- Language:English
-
Abstract:
Chimeric antigen receptor (CAR) T cell therapy has exhibited dramatic anti-tumor efficacy in clinical trials. In this study, we reported the transcriptome profiles of bone marrow cells in four B cell acute lymphoblastic leukemia (B-ALL) patients before and after CD19-specific CAR-T therapy. CD19-CAR-T therapy remarkably reduced the number of leukemia cells, and three patients achieved bone marrow remission (minimal residual disease negative). The efficacy of CD19-CAR-T therapy on B-ALL was positively correlated with the abundance of CAR and immune cell subpopulations, e.g., CD8 T cells and natural killer (NK) cells, in the bone marrow. Additionally, CD19-CAR-T therapy mainly influenced the expression of genes linked to cell cycle and immune response pathways, including the NK cell mediated cytotoxicity and NOD-like receptor signaling pathways. The regulatory network analyses revealed that microRNAs (e.g., miR-148a-3p and miR-375), acting as oncogenes or tumor suppressors, could regulate the crosstalk between the genes encoding transcription factors (TFs; e.g., JUN and FOS) and histones (e.g., HIST1H4A and HIST2H4A) involved in CD19-CAR-T therapy. Furthermore, many long non-coding RNAs showed a high degree of co-expression with TFs or histones (e.g., FOS and HIST1H4B) and were associated with immune processes. These transcriptome analyses provided important clues for further understanding the gene expression and related mechanisms underlying the efficacy of CAR-T immunotherapy.
